US2013210905A1PendingUtilityA1

Selective Ablation of Pain-Sensing Neurons by Administration of a Vanilloid Receptor Agonist

61
Assignee: DEPT OF HEALTH AND HUMAN SERVICES THE GOV OF THE U S OF AMERICA AS REPRESENTED BY THE SECRETARY OFPriority: Mar 22, 2001Filed: Dec 17, 2012Published: Aug 15, 2013
Est. expiryMar 22, 2021(expired)· nominal 20-yr term from priority
Inventors:Michael J. IadarolaZoltan OlahLaszlo Karai
A61K 31/16A61P 29/00A61K 31/357A61K 31/165A61K 31/167
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods and kits for the selective ablation of pain-sensing neurons. The methods comprise administration of a vanilloid receptor agonist to a ganglion in an amount that causes death of vanilloid receptor-bearing neurons. Accordingly, the present invention provides methods of controlling pain and inflammatory disorders that involve activation of vanilloid receptor-bearing neurons.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating pain in a patient comprising administering a vanilloid receptor-1 (VR1) agonist to the patient, wherein the VR1 agonist is administered to a ganglion. 
     
     
         2 . The method of  claim 1 , wherein the patient has post-herpetic neuralgia. 
     
     
         3 . The method of  claim 1 , wherein the patient has trigeminal neuralgia. 
     
     
         4 . The method of  claim 1 , wherein the patient has neuropathic pain. 
     
     
         5 . The method of  claim 1 , wherein the patient has cancer. 
     
     
         6 . The method of  claim 1 , wherein the patient has a chronic viral infection. 
     
     
         7 . The method of  claim 1 , wherein the patient has an inflammatory disease. 
     
     
         8 . The method of  claim 1 , wherein the ganglion is a dorsal root ganglion. 
     
     
         9 . The method of  claim 1 , wherein the ganglion is a trigeminal ganglion. 
     
     
         10 . The method of  claim 1 , wherein the ganglion is an autonomic ganglion. 
     
     
         11 . The method of  claim 1 , wherein the VR1 agonist is injected into the ganglion. 
     
     
         12 . The method of  claim 1 , wherein the VR1 agonist is injected into a nerve root. 
     
     
         13 . The method of  claim 1 , wherein the VR1 agonist is capsaicin. 
     
     
         14 . The method of  claim 1 , wherein the VR1 agonist is resiniferatoxin. 
     
     
         15 . The method of  claim 1 , wherein the VR1 agonist is administered in an amount from about 50 nanograms to about 50 micrograms. 
     
     
         16 . The method of  claim 1 , wherein the VR1 agonist is administered in an amount from about 100 nanograms to about 500 micrograms. 
     
     
         17 . The method of  claim 1 , wherein the VR1 agonist is administered in an amount from 200 nanograms to 1 microgram. 
     
     
         18 . The method of  claim 1 , further comprising administering a local anesthetic. 
     
     
         19 . The method of  claim 18 , wherein the local anesthetic is lidocaine, bupivicaine, tetracaine, or ropivicaine. 
     
     
         20 . The method of  claim 1 , further comprising administering an imaging contrast agent or dye. 
     
     
         21 . The method of  claim 1 , wherein the patient is a human. 
     
     
         22 . The method of  claim 1 , wherein the patient is a dog, horse, cat, cow, sheep, pig, or rabbit. 
     
     
         23 . A kit for injecting a VR-1 agonist into a ganglion, the kit comprising the VR-1 agonist and a local anesthetic.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.